Any current/future new fundraising through debt or equity?

The company does not anticipate requiring additional debt or equity for its expansion plans in the near future. Currently, they have enough funds to support their growth for the next 2.5 years. Future fundraising might be considered only if a significant acquisition opportunity arises. The ongoing expansion plan for 100 labs and 8-9 major centers is expected to be funded without needing extra capital. They are undertaking a preferential share issue of Rs. 104 crore, with contributions from strategic investors, promoters, and company insiders to support ambitious expansion projects.

Any current/future capex/capital investment/strategic investment?

Chandan Healthcare is investing in setting up a dedicated molecular genome lab at the Delhi facility for advanced genetics and molecular testing. Recently secured prime real estate in Mumbai, Chandigarh, and Calcutta for new major processing laboratories to increase capacity and reduce logistics cost. Planning to establish 100 new strategically located collection and processing laboratories across 17 states within 2-3 years. Launching over 1,000 new franchise collection points in Tier 1, 2, and 3 cities across 17 states. Capital investment per lab outside Jeena Sikho's hospital is approximatel

Future growth expectations in sales/revenue/volumes?

Chandan Healthcare targets revenue growth with the diagnostic business expected to grow faster than the pharmacy business, shifting the revenue mix towards diagnostics (currently 60-40, expected up to 80-20 in 3 years). Plans to open 100 new labs in the next 2.5-3 years, with 2-3 labs starting every month and 2-3 comprehensive diagnostic centers annually. Expansion across 17 states, including major cities like Mumbai, Kolkata, and Chandigarh with new lab facilities. Exclusive 5-year partnership with Jeena Sikho to provide diagnostic services to their 50 hospitals and 150+ clinics across

Future growth expectations in earnings/operating earnings/profits/EPS?

Chandan Healthcare targets a net profit and EBITDA growth of more than 20%-25% year-on-year consistently. The company aims to maintain or exceed an EBITDA margin of around 35% by the end of FY'26. Diagnostic business EBITDA margin is strong at 34.22%, contributing to overall margin expansion. Expansion plans include opening 35-40 labs annually, 100 labs targeted in 3 years, aiding revenue and profit growth. Partnership with Jeena Sikho expected to generate Rs. 25-50 crores annually, with healthy margins (~80%) contributing positively to earnings. Pharmacy EBITDA expected to improve from 5.2% t

Current/ Expected Orderbook/ Pending Orders?

The company is aggressively expanding its diagnostic business with plans to open 2-3 labs every month, targeting over 100 labs in the next 2.5 to 3 years. Currently, 8 comprehensive diagnostic centers are operational or about to start by end of FY'26. Space has already been taken for labs in Mumbai, Kolkata, and Chandigarh. The company is also expanding via franchise with plans for over 1,000 franchises across 17 states. The partnership with Jeena Sikho covers collections from 34 units initially, with more to come as Jeena Sikho plans 350 hospitals and clinics in 3 years. MOU to add 250 beds i

Chandan Healthcare LtdQ2 FY26Healthcare Services

Chandan Healthcare Ltd Q2 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹235P/E: 21.9Market Cap: ₹576 CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Chandan Healthcare targets revenue growth with the diagnostic business expected to grow faster than the pharmacy business, shifting the revenue mix towards diagnostics (currently 60-40, expected up to 80-20 in 3 years).
Plans to open 100 new labs in the next 2.5-3 years, with 2-3 labs starting every month and 2-3 comprehensive diagnostic centers annually.
Expansion across 17 states, including major cities like Mumbai, Kolkata, and Chandigarh with new lab facilities.
Exclusive 5-year partnership with Jeena Sikho to provide diagnostic services to their 50 hospitals and 150+ clinics across 17 states, expected to contribute Rs. 25-50 crore per year.
Franchise model expansion targeting 1,000+ new franchise collection points to increase reach in Tier 1, 2, 3 cities.
EBITDA and net profit growth targets are over 20%-25% annually with an aim to maintain or exceed a consolidated EBITDA margin of 35% by FY'26.
IPO planned for FY'27-28 enabled by strong growth and profitability.

Margin guidance

Category 1

Chandan Healthcare targets a net profit and EBITDA growth of more than 20%-25% year-on-year consistently.
The company aims to maintain or exceed an EBITDA margin of around 35% by the end of FY'26.
Diagnostic business EBITDA margin is strong at 34.22%, contributing to overall margin expansion.
Expansion plans include opening 35-40 labs annually, 100 labs targeted in 3 years, aiding revenue and profit growth.
Partnership with Jeena Sikho expected to generate Rs. 25-50 crores annually, with healthy margins (~80%) contributing positively to earnings.
Pharmacy EBITDA expected to improve from 5.2% to over 10% in the next 6 months, supporting overall profitability.
IPO planned in April 2027 to support further growth and consolidation.
Continuous investment in franchise and comprehensive diagnostic centers to fuel sustained earnings growth.

See what Chandan Healthcare Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company does not anticipate requiring additional debt or equity for its expansion plans in the near future.
Currently, they have enough funds to support their growth for the next 2.5 years.
Future fundraising might be considered only if a significant acquisition opportunity arises.
The ongoing expansion plan for 100 labs and 8-9 major centers is expected to be funded without needing extra capital.
They are undertaking a preferential share issue of Rs. 104 crore, with contributions from strategic investors, promoters, and company insiders to support ambitious expansion projects.

Order book

The company is aggressively expanding its diagnostic business with plans to open 2-3 labs every month, targeting over 100 labs in the next 2.5 to 3 years.
Currently, 8 comprehensive diagnostic centers are operational or about to start by end of FY'26.
Space has already been taken for labs in Mumbai, Kolkata, and Chandigarh.
The company is also expanding via franchise with plans for over 1,000 franchises across 17 states.
The partnership with Jeena Sikho covers collections from 34 units initially, with more to come as Jeena Sikho plans 350 hospitals and clinics in 3 years.
MOU to add 250 beds in Gorakhpur hospital within 2 years.
IPO planned in FY 2027-28, with capacity utilization expected to reach 90% by then.
No immediate requirement for additional debt or equity in the next 2 years for expansion.

See what Chandan Healthcare Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Chandan Healthcare is investing in setting up a dedicated molecular genome lab at the Delhi facility for advanced genetics and molecular testing.
Recently secured prime real estate in Mumbai, Chandigarh, and Calcutta for new major processing laboratories to increase capacity and reduce logistics cost.
Planning to establish 100 new strategically located collection and processing laboratories across 17 states within 2-3 years.
Launching over 1,000 new franchise collection points in Tier 1, 2, and 3 cities across 17 states.
Capital investment per lab outside Jeena Sikho's hospital is approximately Rs. 50 lakhs (including renovation, security, rental).
Labs inside Jeena Sikho require about Rs. 30 lakhs investment in machines.
No significant additional debt or equity expected for expansion for next 2 years; raised Rs. 104 crore through preferential shares for expansion.
A 250-bed hospital is planned in Gorakhpur with an MOU; construction timeline is about 2 years.
IPO planned for April 2027, post achieving 90% bed occupancy and scaling to ~850 beds.

Track Chandan Healthcare Ltd — get its next earnings analysis in your feed

How does Chandan Healthcare Ltd rank vs peers in Healthcare Services?

Pro feature

ThisChandan Healthcare Ltd

Rev 2Mar 1

See where Chandan Healthcare Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Chandan Healthcare Ltd rank in Healthcare Services?

Compare Chandan Healthcare Ltd against every Healthcare Services company (Q2 FY26) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Chandan Healthcare Ltd's management said in earlier quarters

Others in Healthcare Services this season

Rainbow Childrens Medicare Ltd (Q2 FY27)
Year-on-year (YoY) growth in revenue: 23.2% . Key investor presentation takeaways from Rainbow Childrens Medicare Ltd's Q2 FY27 investor presentation — and how
Narayana Hrudayalaya Ltd (Q2 FY27)
Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27
Artemis Medicare Services Ltd (Q2 FY27)
Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service
Max Healthcare Institute Ltd (Q2 FY27)
Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio

Compare:vs Apollo Hospitals Enterprise Ltd vs Manipal Health Enterprises Ltd vs Max Healthcare Institute Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →